ATE458047T1 - Verfahren zur verstärkung der oligonucleotid- vermittelten nucleinsäuresequenzänderung unter verwendung von zusammensetzungen mit einem hydroxyharnstoff - Google Patents

Verfahren zur verstärkung der oligonucleotid- vermittelten nucleinsäuresequenzänderung unter verwendung von zusammensetzungen mit einem hydroxyharnstoff

Info

Publication number
ATE458047T1
ATE458047T1 AT03716412T AT03716412T ATE458047T1 AT E458047 T1 ATE458047 T1 AT E458047T1 AT 03716412 T AT03716412 T AT 03716412T AT 03716412 T AT03716412 T AT 03716412T AT E458047 T1 ATE458047 T1 AT E458047T1
Authority
AT
Austria
Prior art keywords
hydroxyurea
nucleic acid
acid sequence
compositions containing
sequence change
Prior art date
Application number
AT03716412T
Other languages
English (en)
Inventor
Eric Kmiec
Hetal Parekh-Olmedo
Erin Brachman
Original Assignee
Univ Delaware
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Delaware filed Critical Univ Delaware
Application granted granted Critical
Publication of ATE458047T1 publication Critical patent/ATE458047T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT03716412T 2002-03-07 2003-03-07 Verfahren zur verstärkung der oligonucleotid- vermittelten nucleinsäuresequenzänderung unter verwendung von zusammensetzungen mit einem hydroxyharnstoff ATE458047T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US36305402P 2002-03-07 2002-03-07
US36305302P 2002-03-07 2002-03-07
US36334102P 2002-03-07 2002-03-07
US41698302P 2002-10-07 2002-10-07
PCT/US2003/007217 WO2003075856A2 (en) 2002-03-07 2003-03-07 Methods, compositions, and kits for enhancing oligonucleotide-mediated nucleic acid sequence alteration using compositions comprising a histone deacetylase inhibitor, lambda phage beta protein, or hydroxyurea

Publications (1)

Publication Number Publication Date
ATE458047T1 true ATE458047T1 (de) 2010-03-15

Family

ID=27808811

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03716412T ATE458047T1 (de) 2002-03-07 2003-03-07 Verfahren zur verstärkung der oligonucleotid- vermittelten nucleinsäuresequenzänderung unter verwendung von zusammensetzungen mit einem hydroxyharnstoff

Country Status (9)

Country Link
US (1) US7566535B2 (de)
EP (1) EP1490013B1 (de)
JP (1) JP2005518817A (de)
AT (1) ATE458047T1 (de)
AU (1) AU2003220119A1 (de)
CA (1) CA2478479A1 (de)
DE (1) DE60331297D1 (de)
IL (1) IL163875A0 (de)
WO (1) WO2003075856A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI319387B (en) 2002-04-05 2010-01-11 Astrazeneca Ab Benzamide derivatives
US20070072815A1 (en) * 2004-05-04 2007-03-29 Kmiec Eric B Methods and kits to increase the efficiency of oligonucleotide-directed nucleic acid sequence alteration
WO2010030171A1 (en) * 2008-09-11 2010-03-18 Keygene N.V. Method for diagnostic marker development
US8993328B2 (en) * 2008-09-22 2015-03-31 Rutgers, The State University Of New Jersey Media conditioning for improving gene delivery efficiency to differentiating embryonic stem cells
EP4331618A3 (de) 2014-05-09 2024-06-12 Yale University Hyperverzweigte polyglycerolbeschichtete partikel und verfahren zur herstellung und verwendung davon
US11918695B2 (en) 2014-05-09 2024-03-05 Yale University Topical formulation of hyperbranched polymer-coated particles
US12359197B2 (en) 2014-12-12 2025-07-15 Etagen Pharma, Inc. Compositions and methods for editing nucleic acids in cells utilizing oligonucleotides
JP2018500935A (ja) * 2014-12-22 2018-01-18 ウニヴェルズィテート チューリッヒ 細胞壁を有する真核細胞における膜タンパク質の指向性進化
EP3416976A2 (de) 2016-02-16 2018-12-26 Yale University Zusammensetzungen zur verbesserung von gezielter geneditierung und verfahren zur verwendung davon
JP7308380B2 (ja) * 2017-01-10 2023-07-14 クリスティアーナ ケア ジーン エディティング インスティテュート，インコーポレイテッド 遺伝子編集技術を用いたインビトロ部位特異的変異導入のための方法
WO2018187493A1 (en) 2017-04-04 2018-10-11 Yale University Compositions and methods for in utero delivery
JP2022539861A (ja) * 2019-07-08 2022-09-13 ライフ テクノロジーズ コーポレーション 細胞培養を増強するための組成物および方法
WO2021207673A1 (en) * 2020-04-09 2021-10-14 The Regents of the University of Colorodo, a body corporate Compositions, methods and uses for production of hematopoietic stem cells (hscs)

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US119570A (en) * 1871-10-03 Improvement in coopers crozes and howels
US217377A (en) * 1879-07-08 hislop
US51270A (en) * 1865-11-28 Improvement in children s bedclothes-retainers
US143052A (en) * 1873-09-23 Improvement in flexible vertically-extensible attachments for boats
US5139941A (en) * 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5955363A (en) * 1990-01-03 1999-09-21 Promega Corporation Vector for in vitro mutagenesis and use thereof
US5432272A (en) * 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
US6136601A (en) * 1991-08-21 2000-10-24 Epoch Pharmaceuticals, Inc. Targeted mutagenesis in living cells using modified oligonucleotides
US5962426A (en) * 1993-06-25 1999-10-05 Yale University Triple-helix forming oligonucleotides for targeted mutagenesis
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
EP0733059B1 (de) * 1993-12-09 2000-09-13 Thomas Jefferson University Verbindungen und verfahren zur ortsspezifischen mutation in eukaryotischen zellen
US5604090A (en) * 1994-06-06 1997-02-18 Fred Hutchinson Cancer Research Center Method for increasing transduction of cells by adeno-associated virus vectors
US5780296A (en) * 1995-01-17 1998-07-14 Thomas Jefferson University Compositions and methods to promote homologous recombination in eukaryotic cells and organisms
JP3770333B2 (ja) * 1995-03-15 2006-04-26 大日本住友製薬株式会社 組換えｄｎａウイルスおよびその製造方法
US5776744A (en) * 1995-06-07 1998-07-07 Yale University Methods and compositions for effecting homologous recombination
US5912340A (en) * 1995-10-04 1999-06-15 Epoch Pharmaceuticals, Inc. Selective binding complementary oligonucleotides
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US6025155A (en) 1996-04-10 2000-02-15 Chromos Molecular Systems, Inc. Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US5760012A (en) * 1996-05-01 1998-06-02 Thomas Jefferson University Methods and compounds for curing diseases caused by mutations
US5888983A (en) * 1996-05-01 1999-03-30 Thomas Jefferson University Method and oligonucleobase compounds for curing diseases caused by mutations
US5731181A (en) * 1996-06-17 1998-03-24 Thomas Jefferson University Chimeric mutational vectors having non-natural nucleotides
WO1997047307A1 (en) 1996-06-14 1997-12-18 The Uab Research Foundation Use of histone deacetylase inhibitors to activate transgene expression
US5928638A (en) * 1996-06-17 1999-07-27 Systemix, Inc. Methods for gene transfer
US6057102A (en) * 1996-08-08 2000-05-02 The Aaron Diamond Aids Research Center HIV coreceptor mutants
AU4966997A (en) * 1996-11-18 1998-06-10 Takeshi Imanishi Novel nucleotide analogues
WO1998026060A2 (en) * 1996-12-12 1998-06-18 Julianna Lisziewicz Materials and methods for gene transfer
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US6043389A (en) * 1997-03-11 2000-03-28 Mor Research Applications, Ltd. Hydroxy and ether-containing oxyalkylene esters and uses thereof
US6387673B1 (en) 1997-05-01 2002-05-14 The Salk Institute For Biological Studies Compounds useful for the modulation of processes mediated by nuclear hormone receptors, methods for the identification and use of such compounds
AUPO721997A0 (en) 1997-06-06 1997-07-03 Queensland Institute Of Medical Research, The Anticancer compounds
US6821759B1 (en) * 1997-06-23 2004-11-23 The Rockefeller University Methods of performing homologous recombination based modification of nucleic acids in recombination deficient cells and use of the modified nucleic acid products thereof
EP2341057A3 (de) 1997-09-12 2011-11-23 Exiqon A/S Oligonukleotidanaloga
US6262116B1 (en) 1998-01-23 2001-07-17 Sloan-Kettering Institute For Cancer Research Transcription therapy for cancers
US6010907A (en) 1998-05-12 2000-01-04 Kimeragen, Inc. Eukaryotic use of non-chimeric mutational vectors
US6004804A (en) * 1998-05-12 1999-12-21 Kimeragen, Inc. Non-chimeric mutational vectors
HUP0103985A2 (hu) 1998-10-13 2002-02-28 Fujisawa Pharmaceutical Co., Ltd. Ciklikus tetrapeptid, és annak felhasználása
CA2346152A1 (en) 1998-10-16 2000-04-27 Novartis Ag Promotion of self-renewal and improved gene transduction of hematopoietic stem cells by histone deacetylase inhibitors
WO2000024917A1 (en) 1998-10-28 2000-05-04 University Of Washington Targeted gene modification by parvoviral vectors
AU2832100A (en) 1999-02-24 2000-09-14 N.V. Kema Combustion unit for combusting a liquid fuel and a power generating system comprising such combustion unit
AU3715900A (en) 1999-03-02 2000-09-21 Liposome Company, Inc., The Encapsulation of bioactive complexes in liposomes
JP4269041B2 (ja) 1999-03-02 2009-05-27 国立大学法人九州工業大学 新規な環状テトラペプチド誘導体とその医薬用途
DK1159415T3 (da) 1999-03-04 2010-05-03 Revivicor Inc Genetisk modifikation af somatiske celler og anvendelse deraf
CN1350542A (zh) 1999-03-18 2002-05-22 埃克西库恩公司 木－lna类似物
WO2000071703A2 (en) 1999-05-03 2000-11-30 Methylgene Inc. Inhibition of histone deacetylase
ATE356824T1 (de) 1999-05-04 2007-04-15 Santaris Pharma As L-ribo-lna analoge
US6261841B1 (en) * 1999-06-25 2001-07-17 The Board Of Trustees Of Northwestern University Compositions, kits, and methods for modulating survival and differentiation of multi-potential hematopoietic progenitor cells
JP2001064177A (ja) 1999-08-16 2001-03-13 Schering Ag ベンズアミド誘導体を有効成分とする製剤
US6271360B1 (en) * 1999-08-27 2001-08-07 Valigen (Us), Inc. Single-stranded oligodeoxynucleotide mutational vectors
JP2001081031A (ja) 1999-08-30 2001-03-27 Schering Ag 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤
CA2383885A1 (en) 1999-09-08 2001-03-15 Sloan-Kettering Institute For Cancer Research Crystal structure of a deacetylase and inhibitors thereof
KR20020059393A (ko) 1999-09-08 2002-07-12 제임스 에스. 쿼크 새로운 부류의 세포분화제 및 히스톤 데아세틸라아제, 및이의 사용 방법
AR025996A1 (es) 1999-10-07 2002-12-26 Valigen Us Inc Plantas no transgenicas resistentes a los herbicidas.
CA2391129A1 (en) 1999-11-10 2001-05-17 The Uab Research Foundation Lentiviral vector transduction of hematopoietic stem cells
KR20100035666A (ko) 1999-11-23 2010-04-05 메틸진 인크. 히스톤 디아세틸라제의 억제제
WO2001049240A2 (en) 2000-01-05 2001-07-12 Novartis Ag Hydrogels
US7288567B2 (en) 2000-03-24 2007-10-30 Methylgene Inc. Inhibitors of histone deacetylase
OA12240A (en) * 2000-03-27 2006-05-10 Univ Delaware Targeted chromosomal genomic alterations with modified single stranded oligonucleotides.
US6936467B2 (en) 2000-03-27 2005-08-30 University Of Delaware Targeted chromosomal genomic alterations with modified single stranded oligonucleotides
EP1170008A1 (de) 2000-07-07 2002-01-09 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Valproinsäure und dessen Derivate als Inhibitoren der Histone deacetylase
ATE425177T1 (de) 2000-07-17 2009-03-15 Astellas Pharma Inc Reduziertes fk228 und seine verwendung
EP1364008A2 (de) 2000-07-27 2003-11-26 University Of Delaware Verfahren zur verbesserung gezielter genmanipulationen mit hilfe von oligonukleotiden
CA2419322C (en) * 2000-08-14 2012-10-23 Donald L. Court Enhanced homologous recombination mediated by lambda recombination proteins
US20020119570A1 (en) 2000-09-25 2002-08-29 Kyonggeun Yoon Targeted gene correction by single-stranded oligodeoxynucleotides
US7312247B2 (en) 2001-03-27 2007-12-25 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors

Also Published As

Publication number Publication date
IL163875A0 (en) 2005-12-18
WO2003075856A3 (en) 2004-06-24
JP2005518817A (ja) 2005-06-30
AU2003220119A1 (en) 2003-09-22
CA2478479A1 (en) 2003-09-18
DE60331297D1 (de) 2010-04-01
WO2003075856A2 (en) 2003-09-18
US20030207451A1 (en) 2003-11-06
EP1490013A4 (de) 2005-12-28
US7566535B2 (en) 2009-07-28
EP1490013B1 (de) 2010-02-17
EP1490013A2 (de) 2004-12-29

Similar Documents

Publication Publication Date Title
ATE458047T1 (de) Verfahren zur verstärkung der oligonucleotid- vermittelten nucleinsäuresequenzänderung unter verwendung von zusammensetzungen mit einem hydroxyharnstoff
DE59712890D1 (de) Neues gen für eine aminosäure-deacetylase mit spezifität für n-acetyl-l-phosphinothricin, ihre isolierung und verwendung
DE69701671D1 (de) Verfahren und zusammenstellungen zur sequenzbestimmung von nukleinsäuremolekulen
DE60326012D1 (de) Verfahren zur Konzentration von Proteinen
DE69932832D1 (de) Antagonisten auf rezeptorgrundlage und verfahren zur deren herstellung und verwendung
ATE531796T1 (de) Verfahren und zusammensetzungen zur verwendung von zinkfinger-endonukleasen zur verbesserung der homologen rekombination
DE602005022830D1 (de) Weniger immunogene bindungsmoleküle
SE0301951D0 (sv) New method
ATE401422T1 (de) Verfahren zur erzeugung einer bibliothek aus bakterienklonen mit unterschiedlichen genexpressionsniveaus
DE602007009498D1 (de) Neue fluoreszenzproteine und verfahren zur verwendung davon
ATE490314T1 (de) Verfahren zur förderung der homologen rekombination somatischer zellen und verfahren zur konstruktion eines spezifischen antikörpers
DE60333032D1 (de) Screening-verfahren zur identifizierung wirksamer prä-trans-spleissmoleküle
SG155774A1 (en) Method to generate or determine nucleic acid tags corresponding to the terminal ends of dna molecules using sequences analysis of gene expression (terminal sage)
ATE474922T1 (de) Fluoreszenzproteine aus copepoda-spezies und verfahren zur verwendung davon
ATE340257T1 (de) Histonedeacetylase 9
ATE488252T1 (de) Erhöhte transduktion mit abc- transportersubstratenhemmern
ATE408029T1 (de) Verfahren zur herstellung und identifizierung löslicher proteindomänen
ATE391727T1 (de) Verfahren zur identifikation von modulatoren des humanen orexin-2-rezeptors
WO2005040215A3 (en) Ovomucoid promoters and mehtods of use
DE69927400D1 (de) Pge synthase und verfahren und mitteln zur modulation deren aktivität
ATE394360T1 (de) Verfahren zur verminderung von von der verwendung von fluorphosphitkatalysatoren herruehrenden fluoridverunreinigungen
DE60232346D1 (de) Verfahren zur weithin ungestützten verbrennung von petroleumkoks
DE60330564D1 (de) Verfahren und konstrukte zur expression von clostripain mit hoher ausbeute
NO20055210L (no) Inhibitorproteiner av en protease og anvendelse derav
DE60323120D1 (de) Verfahren zur modulierung von cytokininabhängigen vorgängen in einer pflanze mittels b3-domäne-proteinen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties